Vaccinogen Inc (VGEN) Financial Statements (2024 and earlier)

Company Profile

Business Address 949 FELL STREET
BALTIMORE, MD 21231
State of Incorp. MD
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2015
MRQ
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 3,040,94273,096
Cash and cash equivalents 3,040,94273,096
Restricted cash and investments 39,56344,394
Inventory, net of allowances, customer advances and progress billings 99,250100,150
Inventory 99,250100,150
Prepaid expense 2,910,476115,522
Total current assets: 6,090,231333,162
Noncurrent Assets
Property, plant and equipment 393,046198,790
Intangible assets, net (including goodwill) 56,022,28962,725,559
Intangible assets, net (excluding goodwill) 56,022,28962,725,559
Deferred tax assets, net 2,000,000 
Other undisclosed noncurrent assets 6,575,810 
Total noncurrent assets: 64,991,14562,924,349
TOTAL ASSETS: 71,081,37663,257,511
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 2,709,5514,220,924
Accounts payable 2,709,5513,357,287
Accrued liabilities  863,637
Debt  4,831,217
Due to related parties  54,099
Other liabilities 653,294 
Other undisclosed current liabilities 2,172,29013,542,779
Total current liabilities: 5,535,13522,649,019
Noncurrent Liabilities
Long-term debt and lease obligation 3,000,000 
Long-term debt, excluding current maturities 3,000,000 
Liabilities, other than long-term debt 856,666 
Accounts payable and accrued liabilities 856,666 
Other undisclosed noncurrent liabilities 8,814,027 
Total noncurrent liabilities: 12,670,693 
Total liabilities: 18,205,82822,649,019
Equity
Equity, attributable to parent 52,875,54840,608,492
Common stock 3,4963,157
Additional paid in capital 164,844,066143,920,855
Accumulated other comprehensive loss (165,888)(36,199)
Accumulated deficit (111,806,126)(103,279,321)
Total equity: 52,875,54840,608,492
TOTAL LIABILITIES AND EQUITY: 71,081,37663,257,511

Income Statement (P&L) (USD)

9/30/2015
TTM
12/31/2014
12/31/2013
Operating expenses (14,831,442)(19,443,556)
Operating loss: (14,831,442)(19,443,556)
Nonoperating income (expense)
(Investment Income, Nonoperating)
 7,753,694(3,074,600)
Interest and debt expense (710,840)(2,062,385)
Loss from continuing operations before equity method investments, income taxes: (7,788,588)(24,580,541)
Other undisclosed loss from continuing operations before income taxes (500,000) 
Loss from continuing operations before income taxes: (8,288,588)(24,580,541)
Income tax expense (238,217) 
Loss from continuing operations: (8,526,805)(24,580,541)
Loss before gain (loss) on sale of properties: (8,526,805)(24,580,541)
Net loss available to common stockholders, basic: (8,526,805)(24,580,541)
Other undisclosed net loss available to common stockholders, diluted (7,753,694) 
Net loss available to common stockholders, diluted: (16,280,499)(24,580,541)

Comprehensive Income (USD)

9/30/2015
TTM
12/31/2014
12/31/2013
Net loss: (8,526,805)(24,580,541)
Other comprehensive income (loss) (129,689)46,953
Comprehensive loss: (8,656,494)(24,533,588)
Other undisclosed comprehensive loss, net of tax, attributable to parent  (46,953)
Comprehensive loss, net of tax, attributable to parent: (8,656,494)(24,580,541)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: